{"name":"SystImmune Inc.","slug":"systimmune-inc","ticker":"","exchange":"","domain":"systimmune.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"BL-M11D1","genericName":"BL-M11D1","slug":"bl-m11d1","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"BL-M11D1","genericName":"BL-M11D1","slug":"bl-m11d1","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNLWFiNVpWSnUtaE1JUEV2MUEweFY3QXAtREViSzdYbXJqUUlwQm5oVEdPYkVnUjVYRUljMGo3SUttbjUwaU5Eek5ZSEIzRHIzb0MyNE5qMGJlSGQtOXB3NGdMUmJmdG13eXRja3h3eUNNYW9tUnZpeGJQeTcxQjMyX08xVFRuNW1qX1M5Ml9rSEJWR1FFb2laNWtQVWdscjlLSGNJMTF4Zzk?oc=5","date":"2026-03-03","type":"trial","source":"BioWorld News","summary":"Systimmune’s iza-bren hits phase III breast cancer goals in China - BioWorld News","headline":"Systimmune’s iza-bren hits phase III breast cancer goals in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQOE1hbktxREJhSzFHZmhXUk05WDc0VW9JRXVhbWxNWmR5ZTAwS05pVWk4WGd1Y1YwbkUtVm5sUkRTTVdVbjNzVmdTS2RnSnRGVEJwbGdTNG5rZW03YkJQcEx3S0dYYl9yZzFGNV83QjVmVDNDckt6elEzb01zU3VvYVhXVkg2YzJDQUpSaGxIWTZmbHNOemRSWktqMFI3cEtWMHVvc1pVSHZkcm9qQ25CMklIWGNWdXRxdnVR?oc=5","date":"2026-02-26","type":"trial","source":"Fierce Biotech","summary":"Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial - Fierce Biotech","headline":"Bristol Myers' $800M ADC hits primary survival endpoints in phase 3 breast cancer trial","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-26","type":"trial","source":"Business Wire","summary":"SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple","headline":"SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iz","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxNQW5KSUVYbVFMWl9fdVgxbVA2OV9mOGxrX2JxOF81bEZTZ05YQ1pTUTNIdnYxTWtrUFRNZ2FOUXVNcS1Sa0Y4Ty1kclRPVTRsMWVwSmp1TWczQ0RsSU0zT2NhdXRoTVdNTURyMUtHY2FlOEstTkdsc2ZkU3VHbXBOUmlMRlQyYWxJRlhsWl9zZVhOTlItbVNFUHJJcGx0UG5q?oc=5","date":"2026-02-26","type":"deal","source":"BioPharma Dive","summary":"Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer - BioPharma Dive","headline":"Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxONmhVaThYYnZSWnk1cDdtOXptWDVFTkMxRVlRLVlhVTFmUm5VNWZnUTVSRVVNS191bmZ6QVRvMlZaX1h6Smp2YnU5RDF0YVhZYTZZTDd2MVRseWlUdmJrOGdrWDBLRGVYTEhmeGpTNXlzdmlPZml5TklObGRCU0dNWkNfWEp4ZFhORmdCTnJqTzVnS25HU2R0YkFkR3BaRmxkNzRmM3BuUzlfTV9ad1VoSURJeV91RGoxNXFWMWtR?oc=5","date":"2026-01-13","type":"pipeline","source":"PR Newswire","summary":"Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference - PR Newswire","headline":"Biokin to Present at J.P. Morgan's 44th Annual Healthcare Conference","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxPNERqNjZCczh0dl9xdmkyYXFhTk1LdXd5N1NlTjRhQ2RLeEJ3OWhWYm96Q29RTHF6NEZXMmRlM1NQX0o4dGJLUFMyRVpra1NmeUtzT1Rkd2RnNzNHc2oyXzF6R2J2aVJadlJZbmR1LTBBYmlnQ3BIT2JJLVZqQnZhOWlNVU9yQWhpYTVJXzdQSQ?oc=5","date":"2025-10-14","type":"pipeline","source":"Contract Pharma","summary":"SystImmune to Receive $250M BMS Milestone - Contract Pharma","headline":"SystImmune to Receive $250M BMS Milestone","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNSzFzVGJEN1ZNMklWRjNnbjJDT0dNczFud3lKbUU0LURuaThUOVpuR0cwanRPX1RlYkozZEp6OHUtaVN1VUJjbDZFWFZHMjUtejhsWWRvUkdyY1VzUWQ0eklHSUt2MWx5Wkstb2NtZjhuZS1KVmpvcVRqMjNpazVsYTJ3bm1TR2tzUWJiejJYS2pwZHNmU04xOFBfN1VRbjh3ZDZfNUxVT3BkUkJhZDEwUnRFcFlKQ0hSUkQ4RXFkMVdjUWpIYzVBeFZqU0M3MHpzdngzSWJfYXQwYi1HN1J2TGg5Vkg?oc=5","date":"2025-10-13","type":"deal","source":"PR Newswire","summary":"SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration - PR Newswire","headline":"SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxNVldERGREekxGT1MtOVh4QnQ4bXgzWlZselhIZ1Mwcm5jT3o3TVdoUkZsMnVxYk5hY2NJckpNblB6Uldpb0tsUnpLYTNOWWs3TE13SC0zZXE1U1hmMjdKY2kycDJ4VkVTRm5yUlRkLUJ0bURUbnNIeFBwckxNaE1JcUw2V0hyaTJQbmNnQWxBV0JTaVpRcVhfUy15dDNhVEZGUkpQZlI2Y0VtS2JaQ1FjcHY1WVRjaG1wX2c?oc=5","date":"2025-10-13","type":"trial","source":"The Pharma Letter","summary":"SystImmune hits $250 million milestone as Bristol Myers backs pivotal study - The Pharma Letter","headline":"SystImmune hits $250 million milestone as Bristol Myers backs pivotal study","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-19","type":"regulatory","source":"Medical Dialogues","summary":"Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan... - Medical Dialogues","headline":"Bristol Myers Squibb, SystImmune gets USFDA Breakthrough Therapy Designation for izalontamab brengitecan...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxNNTh6bldxOFJKcU5ydE1xTTRydUVIWTI5WDlYR1Y1bFlmN0pxcGRCblFNV19nZ0l2RVBhanZJNWJOLThWdjJnVjBwVHJ2UUE5UUtsajVYR1l2WkZSR2hmNG03R2xnT055X2ZMcGw0bnJnSDNPRnNpWV9DVWVDZFZETklzZjNFaENyaU52elliQzFOU19HSjVndnc0WmRzZDhGWlk1cUJUa0xBR1pBcTRSZ3RETko?oc=5","date":"2025-07-28","type":"deal","source":"CoStar","summary":"News | Cancer biotech startup inks full-building deal to expand Seattle-area HQ - CoStar","headline":"News | Cancer biotech startup inks full-building deal to expand Seattle-area HQ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOZUoyUl96SVVmVGY1WHpQZ3NrYWMzekpvaTJHTzJYVFk5UlNFWS13M0hvSmp3RnlBRHhqc25JZkhOR2RnMWVWd28zTVFSb3piOUNUNVk4RTFPSlpvMGktOUZELU1uMnB6eWx0NjItOVVkSUpoazBHczBLOThiTHpneHA5aF8xSmZ5YW1rWXFRX2dHOXN2ZF9rdQ?oc=5","date":"2025-04-17","type":"trial","source":"Oncology Pipeline","summary":"Bristol goes pivotal with SystImmune-partnered conjugate | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"Bristol goes pivotal with SystImmune-partnered conjugate | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPUHk0M0tlQ1I2YndhLUxEYmMyS0UySW03RVE5UmhkckxEdVYyX3UxMlRsa2I5TmdLcnotS1RUOVRXTHpqMFMzN0xZRkxySER2cG5iZGRyZUYwTXp0ZWEwSU9lcjRFZjhfS2ZsMTZMRi1aU3dyMG1FV3BxR2drVjFwd0xLZXIyN1U?oc=5","date":"2023-12-12","type":"deal","source":"Yahoo Finance","summary":"Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree - Yahoo Finance","headline":"Bristol Myers pays SystImmune $800M and adds to pharma’s ‘ADC’ deal spree","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}